Sponsor: ECOG-ACRIN Cancer Research Group
Sponsor Study ID: MM1OA-EA02
Study Title: A Randomized Phase II Study of Venetoclax and HMA-based Therapies for theTreatment of Older and Unfit Adults With Newly Diagnosed for FLT-3 Mutated Acute Myeloid Leukemia (AML): a MyeloMATCH Treatment Trial
CTO #: 104105
NCT Number: NCT06317649
Phase: II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Myeloid and Monocytic Leukemia
Study Objectives: To compare the achievement rate of MRDneg CR of either triplet regimen to azacitidine and venetoclax alone within 4 cycles of therapy